Trials / Completed
CompletedNCT00818844
Role of Nepafenac in Reducing Macular Volume After Epiretinal Membrane Surgery
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Alcon Research · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the macular volume of patients treated with a 3-month course of topical Nepafenac (0.1% solution) to patients treated with a placebo course following epiretinal membrane surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nepafenac 0.1% | NSAID |
| OTHER | BSS | BSS |
Timeline
- Start date
- 2009-01-01
- Primary completion
- 2010-06-01
- Completion
- 2010-06-01
- First posted
- 2009-01-08
- Last updated
- 2015-08-14
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00818844. Inclusion in this directory is not an endorsement.